Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more

Conditions: Alzheimer's Disease
Interventions: dl-alpha-tocopherol, Memantine, Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 13
States / cities: Bay Pines, Florida • Miami, Florida • Iowa City, Iowa + 10 more

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Conditions: Injury
Interventions: Keeping Baby Safe 2-DVD package, The Injury Prevention Program (TIPP) sheets; Behavioral
Lead sponsor: Oregon Center for Applied Science, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more

Conditions: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions: Cemsidomide, Dexamethasone; Drug
Lead sponsor: C4 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 25
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more

Conditions: Knowledge, Attitudes, Practice
Interventions: Responsible Opioid Prescriber Education (ROPES), Active Comparator Control; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Development Delay, Behavior Problem
Interventions: BPT-M, BPT-E; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years and older
Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Loma Linda, California • Portland, Oregon

Conditions: NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions: Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more

Conditions: Hereditary Corneal Dystrophy, Corneal Abnormality, Corneal Dystrophies, Corneal Dystrophies, Hereditary
Interventions: GEB-101 Injection; Genetic
Lead sponsor: GenEditBio Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site
Interventions: Pembrolizumab; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Kenner, Louisiana • New Orleans, Louisiana

Conditions: Breast Cancer
Interventions: Radiation Therapy, Capecitabine; Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Microbiota, Anti-bacterial Agents
Interventions: Levofloxacin, Azithromycin, Cefpodoxime; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions: romidepsin, rituximab, fludarabine phosphate, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: School Readiness
Interventions: School Readiness Coaching Intervention; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Drug Interactions
Interventions: Oxycodone, Hydrocodone, Ondansetron; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 95 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more

Conditions: Peripheral Arterial Disease, Lower Extremity Arterial Disease
Interventions: EverFlex™ Self-Expanding Peripheral Stent System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Modesto, California • Sacramento, California + 20 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: ME-401, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: Deepa Jagadeesh; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Failure, Pulmonary Hypertension
Interventions: Exercise Training; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Complicated Urinary Tract Infections or Pyelonephritis
Interventions: Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Little Rock, Arkansas • Oakland, California • Orange, California + 8 more

Conditions: Breast Cancer
Interventions: doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Breast Cancer, Breast Neoplasms
Interventions: Talazoparib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Parent Training in Child Safety Practices

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Reducing Prescription Opioid Misuse: ROPEs Pilot Trial

The Pro-Parenting Study: Helping Parents Reduce Behavior Problems in Preschool Children With Developmental Delay

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Xeloda (Capecitabine) and External Beam Radiation

Healthy Patients & Effect of Antibiotics

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Clinic-Based School Readiness Coaching

Emergency Department (ED) Drug Interaction in Emergency Department Patients

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

EverFlex Post Approval Study

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Exercise Training to Improve Cardiopulmonary Hemodynamics in Heart Failure Patients

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m